Pyoderma Gangrenosum in a Patient with Ulcerative Colitis: A Case Report

궤양성 대장염에서 다발성으로 발생된 괴저농피증 1예

  • Kang, Kyoung-In (Department of Pediatircs, and Reconstructive Surgery, Chungnam National University College of Medicine) ;
  • You, Sun-Young (Department of Pediatircs, and Reconstructive Surgery, Chungnam National University College of Medicine) ;
  • Oh, Sang-Ha (Department of Plastic and Reconstructive Surgery, Chungnam National University College of Medicine) ;
  • Kim, Jae-Young (Department of Pediatircs, and Reconstructive Surgery, Chungnam National University College of Medicine)
  • 강경인 (충남대학교 의학전문대학원 소아청소년과) ;
  • 유선영 (충남대학교 의학전문대학원 소아청소년과) ;
  • 오상하 (충남대학교 의학전문대학원 성형외과) ;
  • 김재영 (충남대학교 의학전문대학원 소아청소년과)
  • Received : 2009.08.04
  • Accepted : 2009.09.14
  • Published : 2009.09.30

Abstract

Pyoderma gangrenosum associated with ulcerative colitis is an unknown etiology of destructive skin disorder, characterized by progressive painful ulceration. It begins as a erythematous areola or pustule and rapidly progress into a deep ulceration with a discrete and violaceous edge. Early diagnosis followed with non-compressive moist dressing, topical application and systemic immunosuppressants are cornerstone in treating this disease. We report a case of pyoderma gangrenosum exacerbated with incision and drainage in a 15 year old girl with ulcerative colitis. This case emphasizes the importance of early consideration of pyoderma gangrenosum in patient with a background of related systemic disease and minimal traumatized wound care.

만성 염증성 장 질환에서 유발되는 드문 피부 병변인 괴저 농피증은 초기에는 홍반으로 둘러싸인 농포로 시작하지만 빠르게 주변부로 확장되고 염증이 진피 내로 파급 되면서 깊은 궤양이 생겨 피부 함몰을 일으킨다. 초기에 감염성 연부조직염 등으로 오인하여 절개 배농이나 강한 압박 배농을 하게 되면 이 질환의 이상초과민현상 때문에 병변이 악화되는 경향이 있다. 따라서 조기 진단과 습윤-비밀폐 드레싱으로 상처에 가하는 충격을 최소화하면서 상처 부위를 보존하고 2차 세균 감염을 예방하는 것이 초기 치료에 매우 중요하다. 저자들은 궤양성 대장염을 가진 15세 여자에서 발생한 괴저 농피증을 초기 에 압박 배농하여 병변이 빠르게 악화된 증례의 치료 경험을 보고하면서 조기 진단과 초기 치료 대응의 중요성을 강조하고자 한다.

Keywords

References

  1. Papageorgiou KI, Mathew RG, Kaniorou-Larai MG, Yiakoumetis A. Pyoderma gangrenosum in ulcerative colitis: considerations for an early diagnosis. BMJ 2005;331:1323-4. https://doi.org/10.1136/bmj.331.7528.1323
  2. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33:787-802. https://doi.org/10.1016/j.rdc.2007.07.016
  3. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005;81:580-5. https://doi.org/10.1136/pgmj.2004.031633
  4. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008-17. https://doi.org/10.1111/j.1468-3083.2009.03199.x
  5. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998;4:142-8. https://doi.org/10.1002/ibd.3780040209
  6. Fernandez A, Velasco A, Prieto V, Canueto J, Alvarez A, Rodriguez A. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis. Am J Gastroenterol 2008;103:2951-2. https://doi.org/10.1111/j.1572-0241.2008.02094_14.x
  7. Molnar T, Farkas K, Nagy F, Wittmann T. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report. Inflamm Bowel Dis 2008;14:1752-3. https://doi.org/10.1002/ibd.20485
  8. Ermis F, Ozdil S, Akyüz F, Pinarbasi B, Mungan Z. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. Inflamm Bowel Dis 2008;14:1611-3. https://doi.org/10.1002/ibd.20481
  9. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. https://doi.org/10.1053/j.gastro.2007.05.029
  10. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409. https://doi.org/10.1016/S0190-9622(96)90428-4
  11. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55:505-9. https://doi.org/10.1136/gut.2005.074815
  12. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease: a cohort study of 2402 patients. Medicine 2008;87:281-93. https://doi.org/10.1097/MD.0b013e318187cc9c
  13. Wollina U. Pyoderma gangrenosum--a review. Orphanet J Rare Dis 2007;2:19. https://doi.org/10.1186/1750-1172-2-19
  14. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-58. https://doi.org/10.2165/00128071-200203030-00002
  15. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003;32:967-95. https://doi.org/10.1016/S0889-8553(03)00046-3